Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
77 studies found for:    Open Studies | Interventional Studies | "Kidney Failure, Chronic" | United States
Show Display Options
Rank Status Study
1 Recruiting
Has Results
Study of the Effect of Intradialytic Vasopressin on Chronic Hypertension in Patients With End Stage Renal Disease
Conditions: Hypertension;   End Stage Renal Disease
Interventions: Drug: Vasopressin - Very Low Dose;   Drug: Vasopressin - Low Dose;   Drug: Placebo Comparator
2 Recruiting Impact of Rifaximin Therapy on Intestinal Byproducts in End-Stage Renal Disease
Condition: End Stage Renal Disease
Intervention: Drug: Rifaximin
3 Recruiting Impact of Exercise on Cognitive Impairment in End-Stage Renal Disease
Conditions: Cognitive Impairment;   End-Stage Renal Disease
Interventions: Other: Aerobic Exercise;   Procedure: Standard Care Dialysis
4 Recruiting Relypsa For ED Acute Hyperkalemia Control and Reduction (REDUCE)
Condition: Kidney Failure, Chronic
Intervention: Drug: Patiromer 25.2 g
5 Recruiting Renal Osteodystrophy: An Individual Management Approach
Condition: Kidney Failure, Chronic
Interventions: Drug: Alendronate;   Drug: Teriparatide;   Drug: Cinacalcet
6 Recruiting A Cluster-randomized, Pragmatic Trial of Hemodialysis Session Duration
Condition: End Stage Renal Disease
Intervention: Other: Dialysis session of at least 4.25 hours
7 Recruiting Safety and Efficacy of Acthar Gel in an Outpatient Dialysis Population
Condition: End Stage Renal Disease
Intervention: Drug: ACTHAR
8 Recruiting Use of Immune Globulin (IVIG) Plus Rituximab for Desensitization in Highly HLA Sensitized Patients Awaiting Deceased Donor Kidney Transplantation
Condition: End Stage Renal Disease
Intervention: Biological: Rituxan
9 Not yet recruiting Use of Pedometers to Measure and Increase Walking Among Patients With ESRD
Condition: End-stage Renal Disease
Intervention: Behavioral: pedometer
10 Recruiting Renal Allograft Tolerance Through Mixed Chimerism (Belatacept)
Conditions: Kidney Failure, Chronic;   Renal Insufficiency
Interventions: Drug: Belatacept;   Drug: ATG;   Drug: Rituximab;   Radiation: Total Body Irradiation;   Radiation: Thymic Irradiation;   Procedure: Combined Bone Marrow/Kidney Transplantation
11 Recruiting Data Collection for Next Generation Ultrasound Technology Development
Condition: Endstage Renal Disease
Intervention: Device: Ultrasound scan
12 Recruiting Zepatier For Treatment Of Hepatitis C-Negative Patients Who Receive Kidney Transplants From Hepatitis C-Positive Donors
Condition: End Stage Renal Disease
Intervention: Drug: Zepatier
13 Recruiting Clinical Evaluation of a Vascular Anastomotic Connector System
Condition: End Stage Renal Disease
Interventions: Device: Arterial & Venous InterGraft Connectors;   Device: Venous InterGraft Connector
14 Recruiting Your Path to Transplant: A Randomized Control Trial of A Tailored Computer Education Intervention for Living Donor Kidney Transplant
Condition: End Stage Renal Disease
Intervention: Behavioral: Expert System Coaching
15 Recruiting Belatacept in Renal Transplantation With Intermediate Risk Maryland Aggregate Pathology Index (MAPI) Scores
Condition: End-Stage Renal Disease
Intervention: Drug: Belatacept
16 Not yet recruiting Study in End-stage Renal Disease Patients Awaiting Kidney Transplant to Investigate the Potential Effect of IVIG Treatment on the Pharmacokinetics and Pharmacodynamics of LFG316
Condition: Kidney Transplantation
Interventions: Drug: LFG316;   Drug: IVIG
17 Recruiting Trial of Carbamylation in Renal Disease-Modulation With Amino Acid Therapy
Condition: End Stage Renal Failure on Dialysis
Intervention: Dietary Supplement: Amino acid supplementation NephrAmine®
18 Recruiting Product Evaluation for the Effectiveness of the ClearGuard® HD End Cap
Condition: End Stage Renal Disease (ESRD)
Intervention: Device: ClearGuard HD End Cap
19 Recruiting A Clinical Study Comparing Basic Performance and Hemocompatibility of 3 Different Dialyzers in Hemodialysis Patients
Condition: End Stage Renal Disease (ESRD)
Interventions: Device: ELISIO-15H;   Device: Revaclear;   Device: Optiflux
20 Not yet recruiting Reduction of Plasma Free VEGF-A Using Low-dose Bevacizumab in Hemodialysis Patients
Conditions: End Stage Renal Disease;   Hemodialysis Vascular Access Failure
Interventions: Drug: 1.25mg bevacizumab;   Drug: 2.50mg bevacizumab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.